Possible breakthrough for long Covid treatment after study’s ‘really positive’ results – TheLiberal.ie – Our News, Your Views

Possible breakthrough for long Covid treatment after study’s ‘really positive’ results

A new study suggests an experimental drug may significantly reduce fatigue in people with prolonged Covid.

Scientists conducting small clinical trials believe the drug, dubbed AXA1125, may increase energy production in cells and reduce inflammation for people fighting the virus and its aftermath.

They call for larger studies to confirm the results.

While most people who contract Covid-19 typically only experience symptoms for a short time – most people fully recover within 12 weeks, according to the NHS – for others some symptoms last longer. This is known as Long Covid, reports Sky News.

As a new condition, protracted Covid is still not fully understood.

The University of Oxford researchers behind the new study gave 41 patients either the drug AXA1125 or a sham placebo treatment twice a day for four weeks, reports Sky News.

The early-stage Phase 2 study was “double-blind”, meaning neither the scientists nor the patients knew what they were being given until the end of the research.

The study, funded by Axela, the drug’s maker, only looked at patients with clear signs that mitochondrial function was dysfunctional.

The drug’s effect on other symptoms of prolonged COVID remains to be studied.

Margaret Koziel MD, the company’s chief medical officer, said: “We are encouraged by these results, and hope that a treatment for people who suffer from long COVID fatigue may be in sight. We are energized to advance AXA1125 further towards being made available to the millions of patients currently without treatment options,” reports Sky News.

This study could change that if other researchers can replicate the results.

Finally, sufferers can manage their symptoms with a drug such as AXA1125, reports Sky News.

Tell us your thoughts in the Facebook post and share this with your friends.

Share this story with a friend

Share this story

Tell us what you think on our Facebook page